Literature DB >> 23731977

Impact of obesity and insulin-resistance on cirrhosis and portal hypertension.

Annalisa Berzigotti1, Juan G Abraldes.   

Abstract

Obesity is sharply rising worldwide and is increasingly recognized in patients with cirrhosis. This review summarizes the available data documenting a detrimental role of obesity and insulin-resistance on the risk of appearance of clinical events in patients with cirrhosis. Molecular pathways explaining the harmful effect of obesity and insulin resistance in the natural history of cirrhosis are largely unknown. Increasing knowledge of mechanisms leading to white adipose tissue dysfunction on one side, and to portal hypertension on the other side, allow hypothesizing that a link between the pathophysiology of obesity, insulin resistance and portal hypertension in cirrhosis exists. Mechanisms likely involved in this interplay are discussed in this article.
Copyright © 2013 Elsevier España, S.L. and AEEH y AEG. All rights reserved.

Entities:  

Keywords:  Body mass index; Chronic liver disease; Enfermedad hepática crónica; GPVH; HOMA; HVPG; Varices; Índice de masa corporal

Mesh:

Year:  2013        PMID: 23731977     DOI: 10.1016/j.gastrohep.2013.03.005

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  9 in total

1.  Circulating sCD36 is associated with unhealthy fat distribution and elevated circulating triglycerides in morbidly obese individuals.

Authors:  L Knøsgaard; S B Thomsen; M Støckel; H Vestergaard; A Handberg
Journal:  Nutr Diabetes       Date:  2014-04-07       Impact factor: 5.097

Review 2.  Nutritional issues in patients with obesity and cirrhosis.

Authors:  Luigi Schiavo; Luca Busetto; Manuela Cesaretti; Shira Zelber-Sagi; Liat Deutsch; Antonio Iannelli
Journal:  World J Gastroenterol       Date:  2018-08-14       Impact factor: 5.742

Review 3.  Small Esophageal Varices in Patients with Cirrhosis-Should We Treat Them?

Authors:  Thomas Reiberger; Theresa Bucsics; Rafael Paternostro; Nikolaus Pfisterer; Florian Riedl; Mattias Mandorfer
Journal:  Curr Hepatol Rep       Date:  2018-11-07

Review 4.  Chinese guidelines on the management of liver cirrhosis (abbreviated version).

Authors:  Xiao-Yuan Xu; Hui-Guo Ding; Wen-Gang Li; Jing-Hang Xu; Ying Han; Ji-Dong Jia; Lai Wei; Zhong-Ping Duan; En-Qiang Ling-Hu; Hui Zhuang
Journal:  World J Gastroenterol       Date:  2020-12-07       Impact factor: 5.742

Review 5.  AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review.

Authors:  Heather Patton; Julie Heimbach; Arthur McCullough
Journal:  Clin Gastroenterol Hepatol       Date:  2020-10-22       Impact factor: 11.382

6.  Incidence of insulin resistance and diabetes in patients with portosystemic shunts without liver dysfunction.

Authors:  Ying Li; Gao Yang; Jinwei Qiang; Songqi Cai; Hao Zhou
Journal:  J Int Med Res       Date:  2016-09-29       Impact factor: 1.671

Review 7.  Capsaicin in Metabolic Syndrome.

Authors:  Sunil K Panchal; Edward Bliss; Lindsay Brown
Journal:  Nutrients       Date:  2018-05-17       Impact factor: 5.717

Review 8.  Obesity in the Liver Transplant Setting.

Authors:  Carlos Moctezuma-Velazquez; Ernesto Márquez-Guillén; Aldo Torre
Journal:  Nutrients       Date:  2019-10-23       Impact factor: 5.717

Review 9.  Nonalcoholic Fatty Liver Disease and Sarcopenia: Where Do We Stand?

Authors:  Ivana Mikolasevic; Tajana Pavic; Tajana Filipec Kanizaj; Darija Vranesic Bender; Viktor Domislovic; Zeljko Krznaric
Journal:  Can J Gastroenterol Hepatol       Date:  2020-10-31
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.